Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05543928
Other study ID # CTAP101-CL-3007
Secondary ID
Status Recruiting
Phase Phase 3
First received
Last updated
Start date January 31, 2023
Est. completion date July 2025

Study information

Verified date April 2024
Source OPKO Health, Inc.
Contact Christina Gomes
Phone 747-888-3011
Email cgomes@opko.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a phase 3, multi-center, randomized, double-blind, placebo-controlled study in children with stage 3-4 chronic kidney disease (CKD), secondary hyperparathyroidism (SHPT) and vitamin D insufficiency.


Recruitment information / eligibility

Status Recruiting
Enrollment 108
Est. completion date July 2025
Est. primary completion date July 2025
Accepts healthy volunteers No
Gender All
Age group 8 Years to 17 Years
Eligibility Inclusion Criteria: 1. Cohort 1: Be 12 to <18 years of age and have a body weight of =40 kg; Cohort 2: be 8 to <12 years of age and have a body weight of =20 kg. 2. Be diagnosed with stage 3 to 4 CKD at least six months prior to the screening visit, and have an eGFR of =15 to <60 mL/min/1.73m2 at screening. 3. Be without any disease state or physical condition that might impair evaluation of safety or which, in the investigator's opinion, would interfere with study participation, including: 1. Serum albumin = 3.0 g/dL; 2. Serum transaminase (ALT or SGPT, AST or SGOT) > 2.5 times the upper limit of normal at screening; and, 3. Urinary albumin excretion of >3000 mcg/mg creatinine. 4. Exhibit during the initial or, if necessary, a screening visit after washout: 1. Plasma iPTH >100 pg/mL (stage 3 CKD) or >160 pg/mL (stage 4 CKD) 2. Serum calcium <9.8 mg/dL (corrected for albumin); 3. Serum total 25-hydroxyvitamin D <30 ng/mL; and, 4. Serum phosphorus >2.5 to =5.5 mg/dL (12 to <18 years) or =6.0 mg/dL (ages 8 to <12 years). 5. If taking calcitriol or other 1a-hydroxylated vitamin D analogs, or cinacalcet, be willing to forgo treatment with these agents for the duration of the study and complete an 8-week washout period prior to commencing treatment in the study. 6. If taking >1,000 mg/day of elemental calcium, discontinue or reduce calcium use and/or use non-calcium based therapies for the duration of the study. 7. If receiving =1,700 IU/day nutritional vitamin D (ergocalciferol or cholecalciferol) therapy, must agree to remain on a stable dose during the study. 8. If taking >1,700 IU/day of nutritional vitamin D, must discontinue or decrease the dose to =1,700 IU/day, maintain that dose for the duration of the study, and complete an 8-week washout period prior to commencing treatment in the study provided that serum total 25-hydroxyvitamin D is =30 ng/mL. The washout period is not necessary if serum total 25-hydroxyvitami D is <30 ng/mL. 9. If taking any bone modifying treatment that could interfere with study endpoints, must discontinue use of such agent(s) for the duration of the study. 10. Willing and able to comply with study instructions and commit to all clinic visits for the duration of the study. 11. Female subjects of childbearing potential must be neither pregnant nor lactating and must have a negative urine pregnancy test at the first screening visit. 12. All female subjects of childbearing potential and male subjects with female partners of childbearing potential must agree to use effective contraception (eg, implants, injectables, combined oral contraceptives, intrauterine device, sexual abstinence, vasectomy or vasectomized partner) for the duration of the study. 13. Each subject or their legal representative must be able to read, understand and sign the informed consent form (ICF). Exclusion Criteria: 1. History of or planned kidney transplant or parathyroidectomy. 2. History (prior three months) of serum calcium =9.8 mg/dL. 3. Use of bisphosphonate therapy (denosumab) within six months prior to enrollment. 4. Known previous or concomitant serious illness or medical condition, such as malignancy, human immunodeficiency virus, significant gastrointestinal or hepatic disease or cardiovascular event or hepatitis, or physical condition that in the opinion of the investigator may worsen and/or interfere with participation in the study. 5. History of neurological/psychiatric disorder, including psychotic disorder, or any reason which, in the opinion of the investigator makes adherence to a treatment or follow up schedule unlikely. 6. Known or suspected hypersensitivity to any of the constituents of either investigational product. 7. Currently participating in, or has participated in, an interventional/investigational study within 30 days prior to study screening.

Study Design


Intervention

Drug:
CTAP101
CTAP101 Capsules is an extended-release (ER) oral formulation of calcifediol which was approved as Rayaldee® ER Capsules in June 2016 by the United States (US) Food and Drug Administration (FDA) for the treatment of secondary hyperparathyroidism (SHPT) in adult patients with stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency (VDI), defined as serum total 25-hydroxyvitamin D levels less than 30 ng/mL.
Placebo
Placebo

Locations

Country Name City State
United States Nationwide Childrens Hospital Columbus Ohio

Sponsors (1)

Lead Sponsor Collaborator
OPKO Health, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Numbers of subjects who attained mean decrease in plasma iPTH of 30% from baseline The primary efficacy endpoint is the proportion of subjects in the intent-to- treat (ITT) population (age 8 to <18 years) attaining a mean decrease in plasma iPTH of at least 30% from pre-treatment baseline compared to placebo during the EAP. 26 weeks
Primary Safety and tolerability Safety and tolerability will be evaluated in the safety population by AEs, PEs, VS, hematology and laboratory evaluations, and ECGs. 26 weeks
Primary Pharmacokinetic To assess the pharmacokinetic (PK) profile of 25-hydroxyvitamin D3 after repeated doses of CTAP101 Capsules in pediatric subjects 26 weeks
Secondary Level of serum total 25-hydroxyvitamin D at =30 ng/mL compared to placebo To evaluate the efficacy of repeated dosing with CTAP101 Capsules versus placebo in raising serum total 25-hydroxyvitamin D to =30 ng/mL 26 weeks
Secondary Plasma iPTH mean absolute changes and serum total 25-hydroxyvitamin D To determine the time courses of mean absolute changes from pre-treatment baseline in serum total 25-hydroxyvitamin D and plasma iPTH during administration of repeated doses of CTAP101 Capsules 26 weeks
Secondary Pharmacodynamic effects of repeated doses of CTAP101 Capsules To assess the PD effects of repeated doses of CTAP101 Capsules versus placebo on mean serum calcium (corrected for albumin), serum phosphorus and serum calcium-timesphosphorus (CaxP) product, and the change in mean urine calcium:creatinine ratio 26 weeks
Secondary Incidence of hypercalcemia and hyperphosphatemia To evaluate the safety of CTAP101 Capsules versus placebo with regard to the incidence of hypercalcemia and hyperphosphatemia 26 weeks
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04244474 - Effect of Vitamin D Supplementation on Improvement of Pneumonic Children Phase 1/Phase 2
Recruiting NCT05459298 - ViDES Trial (Vitamin D Extra Supplementation) N/A
Completed NCT04476511 - The Efficacy and the Safety of Vitamin D3 30,000 IU for Loading Dose Schedules Phase 3
Suspended NCT03652987 - Endocrine and Menstrual Disturbances in Women With Polycystic Ovary Syndrome (PCOS)
Completed NCT03920150 - Vitamin D 24'000 IU for Oral Intermittent Supplementation Phase 3
Completed NCT03264625 - The Effects of Oral Vitamin D Supplementation on the Prevention of Peritoneal Dialysis-related Peritonitis Phase 2
Completed NCT04183257 - Effect of Escalating Oral Vitamin D Replacement on HOMA-IR in Vitamin D Deficient Type 2 Diabetics Phase 4
Recruiting NCT05084248 - Vitamin D Deficiency in Adults Following a Major Burn Injury Phase 4
Completed NCT05506696 - Vitamin D Supplementation Study N/A
Completed NCT00092066 - A Study to Evaluate the Safety, Tolerability, and Efficacy of an Investigational Drug and Dietary Supplement in Men and Postmenopausal Women With Osteoporosis (0217A-227) Phase 3
Completed NCT03234218 - Vitamin D Levels in Liver Transplantation Recipients Prospective Observational Study
Completed NCT02906319 - Vitamin D and HbA1c Levels in Diabetic Patients With CKD N/A
Completed NCT02714361 - A Study to Investigate the Effect of Vitamin D3 Supplementation on Iron Status in Iron Deficient Women N/A
Completed NCT03203382 - Corneal Nerve Structure in Sjogren's
Completed NCT02118129 - Vitamin D Among Young Adults: an Intervention Study Using a Mobile 'App'. N/A
Not yet recruiting NCT01419821 - Vitamin D and Its Affect on Growth Rates and Bone Mineral Density Until Age 5 N/A
Completed NCT02275650 - The Role of Narrowband Ultraviolet B Exposure in the Maintenance of Vitamin D Levels During Winter N/A
Completed NCT02187146 - The Effects of Serum Vitamin D and IVF Outcome N/A
Completed NCT01651000 - Safety and Efficacy of CTAP101 to Treat Secondary Hyperparathyroidism in Stage 3 or 4 CKD and Vitamin D Insufficiency Phase 3
Completed NCT01741181 - Vitamin D Supplementation in Patients With Diabetes Mellitus Type 2 Phase 4